Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/Esketamine/Obsessive-Compulsive Disorder (OCD)

Esketamine for Obsessive-Compulsive Disorder (OCD)

1 paper and 1 clinical trial exploring esketamine as a treatment for obsessive-compulsive disorder (ocd).

Compounddissociative

Esketamine

Esketamine (Spravato) is the S-enantiomer of ketamine, approved as an intranasal treatment for treatment-resistant depression and MDD with acute suicidal ideation. It is administered under clinical supervision with post-dose monitoring and has reached over $1.6 billion in annual sales.

Full Esketamine profile
IndicationAbout 1-2% of the population worldwide.

Obsessive-Compulsive Disorder (OCD)

Recent research indicates that psychedelics, particularly psilocybin, are emerging as potential therapeutic agents in the treatment of Obsessive-Compulsive Disorder (OCD). Early clinical trials demonstrate promising results regarding their efficacy and safety, paving the way for future studies in this field.

Full Obsessive-Compulsive Disorder (OCD) profile

Academic Research

1 paper
Open Accessindividual

Repeated intranasal esketamine augmentation in treatment-resistant obsessive-compulsive disorder with comorbid major depressive disorder: a prospective case series

This prospective case series (n=8) examined repeated intranasal esketamine for people with treatment-resistant obsessive-compulsive disorder and comorbid major depressive disorder, and found clear improvement in depression and a smaller, more variable reduction in obsessive-compulsive symptoms. Depression improved earlier than OCD symptoms, and half of the participants met response criteria for each condition.

Published
April 26, 2026
Journal
BMC Psychiatry
Authors
López-Rodríguez, S., Segalàs, C., Real, E., Urretavizcaya, M., Bertolín, S., Menchón, J. M., del Pino Alonso, M.

Clinical Trials

1 trial
RecruitingPhase NA

University of Iowa Interventional Psychiatry Service Patient Registry

Prospective observational registry (n=1000) collecting biomarker and clinical outcome data from patients receiving ECT, TMS/dTMS, racemic ketamine infusions, or intranasal esketamine for treatment‑resistant depression and OCD.

Started
November 2, 2020
Type
observational
Blinding
none
Randomized
No
Registry ID
NCT04480918

Explore further

Search all Esketamine papers Search all Obsessive-Compulsive Disorder (OCD) trials Full Esketamine profile Full Obsessive-Compulsive Disorder (OCD) profile